Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
The Journal of Pharmacology and Experimental Therapeutics|February 14, 2008
Noncompetitive antagonism and inverse agonism as mechanism of action of nonpeptidergic antagonists at primate and rodent CXCR3 chemokine receptorsDennis Verzijl, Stefania Storelli, Danny J Scholten, et al.
Glia|July 22, 2010
Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesionsRuben Van Doorn, Jack Van Horssen, Dennis Verzijl, et al.
The Journal of Biological Chemistry|January 24, 2004
Furin is a chemokine-modifying enzyme: in vitro and in vivo processing of CXCL10 generates a C-terminally truncated chemokine retaining full activityPaul J Hensbergen, Dennis Verzijl, Crina I A Balog, et al.
Life Science Alliance|October 22, 2022
Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor modelsKristel Kemper, Ellis Gielen, Peter Boross, et al.
Oncoimmunology|February 21, 2022
An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulationAlexander Muik, Isil Altintas, Friederike Gieseke, et al.
Journal for Immunotherapy of Cancer|June 10, 2022
DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activityAlexander Muik, Homer C Adams 3rd, Friederike Gieseke, et al.
Ebiomedicine|June 28, 2023
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activityIda H Hiemstra, Kim C M Santegoets, Maarten L Janmaat, et al.
Molecular Cancer Therapeutics|June 30, 2026
Preclinical Comparison of Two CD3xB7H4 Bispecific Antibodies for Solid Tumor Therapy Reveals CD3 Affinity-Dependent Potency and Tolerability TradeoffsLouise A Koopman, Farshid Alemdehy, Stefanie A H de Poot, et al.
Cancer Discovery|February 17, 2022
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid TumorsAlexander Muik, Elena Garralda, Isil Altintas, et al.
Pageof 3